Table 2 Change in bone resorption markers over 28-days.

From: A pilot feasibility randomised controlled trial of bone antiresorptive agents on bone turnover markers in critically ill women

Serum CTX (ng/L*)

Antiresorptive (n = 8)

Placebo (n = 6)

Difference

P-value

Baseline

666 (± 263)

529 (± 221)

–

 

Day 28

340 (± 219)

629 (± 243)

–

 

Total change

 − 326 (± 362)

 + 100 (± 217)

– 426 (− 799 to − 53)

0.03

Percent change

 − 43% (± 40%)

 + 26% (± 55%)

– 69% (− 127% to − 11%)

  1. Data are shown as mean (± standard deviation).
  2. CTX collagen type 1 cross-linked c-telopeptide.
Back to article page